FLT3 and neoplasm: A pan-PIM/FLT3 inhibitor SEL24 [112], a type II FLT3 inhibitor MZH29 [113], a MERTK/FLT3 inhibitor MRX-2843 [114], a BCR-ABL inhibitor ponatinib [115], and a multiple tyrosine kinase inhibitor cabozantinib [116] have exhibited anti-tumor activity in cases with FLT3-TKD, including those with the F691 pointmutation.